
Adverum Biotechnologies, Inc., wholly owned subsidiary of Eli Lilly and Company, is looking for a Technical Development Scientist to join our team in our Redwood City office. This position reports into the Director of Technical Development.
This person will be working with teams across Analytical Development, Process Development, Formulation, and Regulatory Affairs. This role is responsible for designing and executing experiments to support the development of gene therapy products. The Senior Technical Development Scientist I will contribute to analytical method development, product characterization, and process optimization. This individual will analyze and interpret complex scientific data, troubleshoot technical challenges, and collaborate cross-functionally to ensure robust and scalable solutions. The role also includes authoring technical reports and supporting regulatory submissions, while maintaining compliance with industry standards and internal quality systems.
Contract duration: 12 months
Note to Recruiters and Agencies:
All recruiter and agency inquiries must go through Adverum’s internal Talent Acquisition team. Unsolicited resumes sent to Adverum will be considered Adverum's property. Adverum’s Talent Acquisition team must expressly engage agencies for any requisition. Direct contact with hiring managers by agencies will not be tolerated and may affect your ability to work with Adverum in the future.

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.